Benitec Limited (ASX:BLT)(PINK:BNIKF) provided an update today on progress with the substantial Benitec intellectual property (IP) portfolio. This update is in addition to the recent update on the continuing separate Patent Reexamination of the '099 (Graham) patent in the USA.
Mesoblast Limited (ASX:MSB)(PINK:MBLTY) today announced that its United States-based associate company Angioblast Systems Inc. has closed a A$10 million equity-based financing from institutional and sophisticated investors. New investors oversubscribed the financing, with A$3 million coming from existing Angioblast shareholders.
Australia's regenerative medicine company, Mesoblast Limited (ASX:MSB)(PINK:MBLTY), today announced that institutional and sophisticated investors have made a minimum of A$7 million and up to a maximum of A$10 million equity-based investment in its United States associate company, Angioblast Systems Inc. Settlement formalities are expected to be completed in the next seven days.
Australian regenerative medicine company, Mesoblast Limited (ASX:MSB)(PINK:MBLTY), today announced that it has received clearance from the United States Food and Drug Administration (US FDA) for a Phase 2 clinical trial of its allogeneic or "off-the-shelf" adult stem cells in minimally invasive lumbar spinal fusion surgery.
US stocks surged overnight as the Federal Reserve said the economy was leveling out, and it left interest rates unchanged at the end of its two-day policy meeting.
Australian regenerative medicine company, Mesoblast Limited (ASX:MSB)(PINK:MBLTY), today announced that its United States-based associate company Angioblast Systems Inc. has initiated a Phase 2 clinical trial to evaluate the safety and effectiveness of the company's proprietary "off-the-shelf" adult stem cell product Revascor(TM) for improving heart muscle function in patients with the most severe, or class IV, end-stage form of heart failure.
The Directors of Benitec Limited (ASX:BLT)(PINK:BNIKF) are delighted to announce that Dr Peter French will be joining the Benitec team as Chief Scientific Officer (CSO), initially on a part time basis. Dr French will commence this role on 3 August 2009 and will report to the Chief Executive Officer Sue MacLeman.
